title: [Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
abstract: OBJECTIVE
  To evaluate the clinical efficacies of aromatase inhibitors in the treatment of postmenopausal metastatic breast cancer.
  
  
  METHODS
  A total of 148 postmenopausal women (including bilateral ovariectomy) with hormone dependent metastatic breast cancer receiving aromatase inhibitors (letrozole, anastrozole or exemestane) were analyzed retrospectively. Their clinical efficacies were evaluated.
  
  
  RESULTS
  The median progression-free survival (PFS) was 6.5 months and the clinical benefit rate 63.5%. And the rates of PFS of patients on first-line and second-line or above treatments were 9.0 (95% CI: 6.95-11.05) and 3.0 months (95% CI: 1.8-10.1) respectively. The clinical benefit rates of two groups were 74.2% and 26.3% respectively.
  
  
  CONCLUSIONS
  Aromatase inhibitors are both efficacious and well-tolerated for patients of postmenopausal metastatic breast cancer. It may be recommended as a first-line therapy for postmenopausal women with hormone dependent metastatic breast cancer.
authors.affiliation: Department of Breast Disease, Cancer Hospital, Zhengzhou University, Henan 450003, China.
authors.forename: Mengwei
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Department of Breast Disease, Cancer Hospital, Zhengzhou University, Henan 450003, China; Email: ym200678@126.com.
authors.forename: Min
authors.initials: M
authors.lastname: Yan
authors.affiliation: Department of Breast Disease, Cancer Hospital, Zhengzhou University, Henan 450003, China.
authors.forename: Huimin
authors.initials: H
authors.lastname: Lü
authors.affiliation: Department of Breast Disease, Cancer Hospital, Zhengzhou University, Henan 450003, China.
authors.forename: Limin
authors.initials: L
authors.lastname: Niu
authors.affiliation: Department of Breast Disease, Cancer Hospital, Zhengzhou University, Henan 450003, China.
authors.forename: Huiai
authors.initials: H
authors.lastname: Zeng
authors.affiliation: Department of Breast Disease, Cancer Hospital, Zhengzhou University, Henan 450003, China.
authors.forename: Shude
authors.initials: S
authors.lastname: Cui
mesh_terms: D000077384:Anastrozole; D000730:Androstadienes; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms; D018572:Disease-Free Survival; D005260:Female; D006728:Hormones; D006801:Humans; D000077289:Letrozole; D009362:Neoplasm Metastasis; D009570:Nitriles; D017698:Postmenopause; D014230:Triazoles
chemical_list: D000730:Androstadienes; D047072:Aromatase Inhibitors; D006728:Hormones; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole; D000077289:Letrozole; C056516:exemestane